Related Experiment Video
Updated: Apr 18, 2026
11:36
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
9.9K
A fuel partitioning perspective on appetite suppression by GLP-1 receptor agonists
1Monell Chemical Senses Center, Philadelphia, PA 19104, USA.
Trends in Endocrinology and Metabolism: TEM
|April 16, 2026
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may suppress appetite by shifting the body toward burning more fat. Further research is needed to confirm this fuel partitioning hypothesis and its role in appetite regulation.
Area of Science:
- Metabolism and Endocrinology
- Neuroscience and Behavior
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to suppress appetite.
- Current understanding attributes this effect to direct neural actions on food intake regulation.
Purpose of the Study:
- To propose that altered fuel partitioning, specifically increased fat oxidation, contributes to GLP-1RA-mediated appetite suppression.
- To outline research directions for investigating this novel hypothesis.
Main Methods:
- This study is primarily theoretical, proposing a hypothesis and suggesting experimental approaches.
- Future research may involve metabolic studies, neuroimaging, and behavioral analyses in relevant models.
Main Results:
- The article posits a novel mechanism for appetite suppression by GLP-1RAs.
- It suggests that a metabolic shift towards fat oxidation is a key contributing factor.
Conclusions:
- GLP-1RA-induced appetite suppression may involve a shift in fuel utilization towards fat oxidation.
- Further investigation is warranted to validate this metabolic hypothesis and its implications for therapeutic applications.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
914
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
914
01:30Regulation of Food Intake
3.2K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.2K
01:06Oral Hypoglycemic Agents: Glinides
996
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
996
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
994
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
994